Cardio-oncology in Ukraine: experience at Strazhesko Institute of Cardiology

• Authors: Sergey Kozhukhov , Nataliia Dovganych , Ivan Smolanka , Olga Lyhyrda
• Languages of publication: EN

Abstracts

EN

Anticancer therapies have extended the lives of patients with cancer, but for some, this benefit is tempered by cardiovascular complications. Their number is increasing as a result of an improvement in the early diagnosis of cardiotoxicity caused by chemo- and radiotherapy. Therefore prevention, detection, monitoring, and treatment of cancer patients at risk of cardiotoxicity with or without concomitant CV diseases are very important. Cardio-oncology is a new direction in Ukraine for improving clinical outcomes of cancer patients. This review aims to provide an overview of the rationale for setting up a Cardio-Oncology Unit and reflects our own experience establishing this service.

Keywords

EN

cardio-oncology; cardiotoxicity; cardiovascular risk factors

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2018
• Volume: 8
• Issue: 3
• Pages: 65-69

Contributors

author

Sergey Kozhukhov

• Cardio-Oncology Unit, National Scientific Center M.D. Strazhesko Institute of Cardiology, Kyiv, Ukraine

author

Nataliia Dovganych

• Cardio-Oncology Unit, National Scientific Center M.D. Strazhesko Institute of Cardiology, Kyiv, Ukraine

author

Ivan Smolanka

• Ukrainian National Cancer Institute, Kyiv, Ukraine

author

Olga Lyhyrda

• Ukrainian National Cancer Institute, Kyiv, Ukraine

References

• 1. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55(3): 213-220.
• 2. Cardinale D, Biasillo G, Cipolla CM. Curing cancer, saving the heart: a challenge that cardioncology should not miss. Curr Cardiol Rep 2016; 18: 51.
• 3. Tromp J, Steggink LC, Van Veldhuisen DJ et al. Cardio-oncology: progress in diagnosis and treatment of cardiac dysfunction. Clin Pharmacol Ther 2017; 101: 481-490.
• 4. Kim KW, Shinagare AB, Krajewski KM et al. Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management. Korean J Radiol 2015; 16(2): 304-313.
• 5. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 2015; 12(9): 547-558.
• 6. Reports of State Expert Centre of the Ministry of Health of Ukraine [online: www.dec.gov.ua].
• 7. Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al. 2016 ESC Position Paper cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; 37: 2768-2801.
• 8. Plana JC, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27(9): 911-939.
• 9. Herrmann J, Lerman A. An update on cardio-oncology. Trends Cardiovasc Med 2014; 24(7): 285-295.
• 10. Lancellotti P, Suter TM, López-Fernández T et al. Cardio-Oncology Services: rationale, organization and implementation. A report from the ESC Cardio-Oncology council. Eur Heart J 2018; 6. DOI: 10.1093/eurheartj/ehy453 [Epub ahead of print].
• 11. Läubli H, Balmelli C, Bossard M et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015; 3: 11.
• 12. Koelzer VH, Rothschild SI, Zihler D et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer 2016; 4: 13.
• 13. Barac A, Murtagh G, Carver JR et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol 2015; 65: 2739-2746.
• 14. der Meer P, Gietema JA, Suter TM et al. Cardiotoxicity of breast cancer treatment: no easy solution for an important long-term problem. Eur Heart J 2016; 37: 1681-1683.
• 15. Nhola LF, Villarraga HR. Rationale for Cardio-Oncology Units. Rev Esp Cardiol 2017; 70: 583-589.
• 16. Parent S, Pituskin E, Paterson DI. The cardio-oncology program: a multidisciplinary approach to the care of cancer patients with cardiovascular disease. Can J Cardiol 2016; 32: 847-851.
• 17. Borras JM, Albreht T, Audisio R et al. European Policy statement on multidisciplinary cancer care. European Partnership Action Against Cancer: consensus group. J Cancer 2014; 50: 475-480.
• 18. Cubbon RM, Lyon AR. Cardio-oncology: concepts and practice. Indian Heart J 2016; 68(Suppl 1): S770-S785.
• 19. Lancellotti P, Anker SD, Donal E et al. EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry) – EURObservational Research Program of the European Society of Cardiology. Eur Heart J Cardiovasc Imaging 2015; 16: 466-470.

• Document Type: article